GlassScriptPhysician profile
Raymond Lee Halstead
NPI 1548742927
$50,090.92
in general payments reported to CMS, 2019-2025
22 companies · $3,662 in 2025
The $3,662 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13K · 2022: $15K · 2023: $12K · 2024: $6,339 · 2025: $3,662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Travel and Lodging: $4,790 · Food and Beverage: $2,838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,250.00 |
| Travel and Lodging | $4,789.60 |
| Food and Beverage | $2,837.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $46,546.42 | 2021-2025 | |
| Allergan, INC. | $750.00 | 2021 | |
| Insmed, INC. | $720.30 | 2021-2025 | Arikayce, Brinsupri |
| Melinta Therapeutics, LLC | $453.04 | 2021-2025 | Rezzayo, Kimyrsa, Vabomere |
| Merck Sharp & Dohme LLC | $415.09 | 2021-2025 | Zerbaxa, Dificid, Recarbrio |
| Paratek Pharmaceuticals, INC. | $394.53 | 2021-2024 | Nuzyra |
| Viiv Healthcare Company | $239.45 | 2024-2025 | Dovato |
| Gilead Sciences, INC. | $142.36 | 2021-2023 | Veklury |
| Aimmune Therapeutics, INC. | $61.71 | 2024-2025 | Vowst |
| Astellas Pharma US INC | $54.48 | 2021-2022 | |
| Theratechnologies INC. | $47.59 | 2021-2025 | Egrifta |
| Mimedx Group, INC. | $44.55 | 2025 | |
| Convatec INC. | $33.18 | 2024 | |
| Solventum Corporation | $26.14 | 2024 | V.A.C. Veraflo |
| Invivyd INC | $22.86 | 2024 | Pemgarda |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $22.85 | 2023 | |
| Averitas Pharma INC. | $21.64 | 2024 | Qutenza |
| La Jolla Pharmaceutical Company | $21.19 | 2025 | Zevtera |
| Cormedix INC. | $20.17 | 2025 | Defencath |
| Shionogi INC | $18.32 | 2023 | Fetroja |
| Philips North America LLC | $18.04 | 2025 | Vest Therapy Und |
| Janssen Biotech, INC. | $17.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Halstead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.